Dublin, Sept. 04, 2023 (GLOBE NEWSWIRE) -- The "Global Erythropoietin Drugs Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
In the dynamic landscape of healthcare, the global erythropoietin drugs market has emerged as a critical player, fueled by the escalating prevalence of chronic kidney disease and the rising incidence of cancer on a global scale.
With a valuation of USD 10.3 billion in 2022, this market's trajectory is poised for further ascent, projected to achieve a robust CAGR of 5.7% during the forecast period spanning 2023-2031, ultimately reaching a commendable value of USD 17 billion by 2031.
Erythropoietin (EPO) drugs, a vital class of therapeutic agents, bear the responsibility of bolstering red blood cell production within the human body. These medications stand as pillars in the treatment of anemia, particularly in cases involving chronic kidney disease, cancer, or medical procedures such as chemotherapy or dialysis. Emulating the action of the naturally occurring erythropoietin hormone, synthesized by the kidneys to regulate red blood cell generation, EPO drugs bring relief to patients grappling with anemia-related challenges.
Situated at the heart of the pharmaceutical realm, the Erythropoietin (EPO) drugs market operates as a critical facet of the industry, focusing on the creation and distribution of medications aimed at invigorating red blood cell production. In this landscape, EPO drugs assume a role of paramount significance, orchestrating the management of anemia, especially among individuals stricken by chronic kidney disease, cancer, or undergoing intensive procedures like chemotherapy and dialysis.
A tapestry woven from multiple threads, the market's propulsion is attributed to a confluence of factors. The swelling prevalence of chronic kidney disease, compounded by the surge in cancer incidences on a global canvas, fuels the market's momentum. The shifting demographics, coupled with the surge in conditions like diabetes and hypertension, converge to drive the escalating prevalence of chronic kidney disease, thus magnifying the demand for EPO drugs.
Moreover, the arena of oncology has witnessed a marked expansion in the utilization of EPO drugs, as they proffer a crucial hand in managing the anemia intricately linked with cancer and its treatment paradigms.
Advancements in drug delivery systems have also been a key driver in the market. The development of long-acting EPO formulations and sustained-release implants has improved patient convenience and compliance by reducing the frequency of drug administration.
In summary, the EPO drugs market is driven by factors such as the rising prevalence of chronic kidney disease and the increasing use of EPO drugs in oncology. Advancements in drug delivery systems, the entry of biosimilars, and regulatory compliance are key trends shaping the market. As the demand for effective anaemia management continues to rise, the market for EPO drugs is expected to grow further, driven by innovation and adherence to regulatory requirements.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
Key Trends in the Erythropoietin Drugs Market
Rising Prevalence of Chronic Kidney Disease (CKD): The increasing prevalence of CKD, driven by factors such as aging population, diabetes, and hypertension, is a major driver for the growth of the EPO drugs market. CKD often leads to anemia, and EPO drugs are an important treatment option to manage anemia in these patients
Growing Use in Oncology: EPO drugs are widely used in the field of oncology to manage anemia associated with chemotherapy and cancer-related conditions. As the incidence of cancer continues to rise globally, the demand for EPO drugs in cancer care is expected to increase
Advancements in Drug Delivery Systems: The development of new drug delivery systems, such as long-acting EPO formulations and sustained-release implants, is a key trend in the EPO drugs market. These advancements aim to enhance patient convenience and adherence by reducing the frequency of drug administration
Biosimilars and Patent Expirations: The market for EPO drugs has witnessed the entry of biosimilars, which are highly similar versions of the original EPO drugs. The availability of biosimilars has increased competition and led to cost savings for healthcare systems. Additionally, the expiration of patents for some originator EPO drugs has further contributed to market growth
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 140 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value (USD) in 2023 | $10.91 Billion |
| Forecasted Market Value (USD) by 2031 | $17 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
The major companies in the market are as follows:
- Amgen Inc
- Biocon Limited
- Dr. Reddy's Laboratories Ltd
- F. Hoffmann-La Roche AG
- Intas Pharmaceuticals Ltd
- Johnson & Johnson
- LG Chem Ltd
- Pfizer Inc
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Ltd
Patent Analysis
- Analysis by Type of Patent
- Analysis by Publication year
- Analysis by Issuing Authority
- Analysis by Patent Age
- Analysis by CPC Analysis
- Analysis by Patent Valuation
- Analysis by Key Players
Grants Analysis
- Analysis by year
- Analysis by Amount Awarded
- Analysis by Issuing Authority
- Analysis by Grant Application
- Analysis by Funding Institute
- Analysis by NIH Departments
- Analysis by Recipient Organization
Clinical Trials Analysis
- Analysis by Trial Registration Year
- Analysis by Trial Status
- Analysis by Trial Phase
- Analysis by Therapeutic Area
- Analysis by Geography
Funding and Investment Analysis
- Analysis by Funding Instances
- Analysis by Type of Funding
- Analysis by Funding Amount
- Analysis by Leading Players
- Analysis by Leading Investors
- Analysis by Geography
Partnership and Collaborations Analysis
- Analysis by Partnership Instances
- Analysis by Type of Partnership
- Analysis by Leading Players
- Analysis by Geography
Erythropoietin Drugs Market Segmentations
Market Breakup by Drug Type
- Biologics
- Biosimilars
Market Breakup by Product Type
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
Market Breakup by Application
- Haematology
- Kidney Disorder
- Cancer
- Others
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
For more information about this report visit https://www.researchandmarkets.com/r/vcwu4m
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
